TG Therapeutics, Inc. TGTX

57.43 (0.09) (0.16%) as of 25 Sep
Market cap
$8.8B
P/E
18.9×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
616.29 329.00 233.66 2.79 6.69 0.15 0.15 0.15 0.15 0.15
Revenue Growth
87.32% 40.80% 8,290.02% (58.36%) 4,300.66% 0.00% 0.00% 0.00% 0.00% (0.26%)
Cost of Revenue
100.71 38.49 14.13 0.27 0.79 0.37 0.28 0.09 0.08 0.06
Gross Profit
515.57 290.52 219.53 2.52 5.90 0.15 0.15 0.15 0.15 0.15
R&D Expenses
160.22 94.29 76.19 125.35 222.58 165.90 154.18 159.39 102.53 69.23
SG&A Expenses
232.03 154.30 122.71 95.48 128.09 107.85 15.03 15.16 16.33 9.89
Operating Income
123.32 41.93 20.63 (218.32) (344.77) (273.59) (169.05) (174.40) (118.71) (78.97)
Non-operating Income/Expense
(15.93) (16.33) (7.57) (5.50) (3.33) (5.79) (3.82) 0.92 0.24 0.72
Non-operating Interest Expenses
26.73 24.03 12.62 10.19 5.64 6.33 5.29 0.88 0.85 0.32
EBT
107.39 25.59 13.06 (223.81) (348.10) (279.38) (172.87) (173.48) (118.48) (78.25)
Income Tax Provision
(339.79) 2.21 0.39 — — — — — — —
Income after Tax
447.18 23.38 12.67 (223.81) (348.10) (279.38) (172.87) (173.48) (118.48) (78.25)
Dividends (Preferred)
— — — — — — — 0.00 0.00 0.00
Net Income Common
447.18 23.38 12.67 (223.81) (348.10) (279.38) (172.87) (173.48) (118.48) (78.25)
EPS (Basic)
3.10 0.16 0.09 (1.46) (2.63) (2.42) (1.96) (2.15) (1.91) (1.60)
EPS (Diluted)
2.77 0.15 0.09 (1.46) (2.63) (2.42) (1.96) (2.30) (1.91) (1.60)
Shares (Basic, Weighted)
144.32 145.32 141.96 135.41 132.22 115.33 88.37 75.47 62.07 49.04
Shares (Diluted, Weighted)
161.41 160.34 148.51 135.41 132.22 115.33 88.37 75.47 62.07 49.04
Gross Margin
83.66% 88.30% 93.95% 90.48% 88.19% 100.00% 100.00% 100.00% 100.00% 100.00%
EBIT Margin
20.01% 12.74% 8.83% (7,838.99%) (5,154.28%) (179,996.05%) (111,220.39%) (114,736.84%) (78,100.00%) (51,953.29%)
EBT margin
17.43% 7.78% 5.59% (8,036.34%) (5,204.08%) (183,803.29%) (113,730.92%) (114,132.89%) (77,944.74%) (51,482.24%)
Net Profit Margin
72.56% 7.11% 5.42% (8,036.34%) (5,204.08%) (183,803.29%) (113,730.92%) (114,132.89%) (77,944.74%) (51,482.24%)
Free Cash Flow Margin
(4.05%) (12.33%) (13.44%) (6,326.18%) (4,425.70%) (141,357.89%) (87,458.55%) (84,878.29%) (61,685.53%) (40,744.08%)
EBITDA
121.00 37.22 21.20 (216.29) (342.68) (272.32) (168.44) (174.43) (118.57) (78.45)
EBIT
123.32 41.93 20.63 (218.32) (344.77) (273.59) (169.05) (174.40) (118.71) (78.97)
Income from Continuous Operations
447.18 23.38 12.67 (223.81) (348.10) (279.38) (172.87) (173.48) (118.48) (78.25)
Consolidated Net Income/Loss
447.18 23.38 12.67 (223.81) (348.10) (279.38) (172.87) (173.48) (118.48) (78.25)
EPS (Basic, from Continuous Ops)
3.10 0.16 0.09 (1.65) (2.63) (2.42) (1.96) (2.30) (1.91) (1.60)
EPS (Basic, Consolidated)
3.10 0.16 0.09 (1.65) (2.63) (2.42) (1.96) (2.30) (1.91) (1.60)
EPS (Diluted, from Cont. Ops)
2.77 0.15 0.09 (1.65) (2.63) (2.42) (1.96) (2.30) (1.91) (1.60)
Shares (Diluted, Average)
161.41 160.34 148.51 135.41 132.22 115.33 88.37 — 62.07 49.04
EPS (Diluted, Consolidated)
2.77 0.15 0.09 (1.65) (2.63) (2.42) (1.96) (2.30) (1.91) (1.60)
EBITDA Margin
19.63% 11.31% 9.07% (7,766.18%) (5,123.02%) (179,161.18%) (110,815.79%) (114,757.24%) (78,005.92%) (51,609.87%)
Operating Cash Flow Margin
(4.02%) (12.32%) (13.44%) (6,325.67%) (4,419.70%) (141,123.03%) (87,372.37%) (84,819.08%) (61,684.21%) (40,517.76%)

Fold the line items

In millions of $ except per-share values · columns are period end dates